publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
T-DXd
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer
Edoxaban
Impact of frailty in patients with non-valvular atrial fibrillation undergoing catheter ablation
Pexidartinib
Real-world patient experience of pexidartinib for tenosynovial giant-cell tumor
Other/Multi
Augmenting external control arms using Bayesian borrowing: A case study in first-line non-small cell lung cancer
Valemetostat
Effective in vitro evaluation of the risk of histamine release related to valemetostat tosylate using MRGPRX2-expressing cells
T-DXd
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Edoxaban
A disposable edoxaban sensor chip using carbon paste electrode grafted with molecularly imprinted polymer
T-DXd
Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression
T-DXd
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
Dato-DXd
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan